Haleon (LON:HLN) Price Target Raised to GBX 335 at JPMorgan Chase & Co.

Haleon (LON:HLN) had its target price increased by research analysts at JPMorgan Chase & Co. from GBX 315 to GBX 335 in a note issued to investors on Wednesday,London Stock Exchange reports. The firm presently has an “underweight” rating on the stock. JPMorgan Chase & Co.‘s price target would suggest a potential downside of 9.97% from the stock’s current price.

Other equities analysts have also issued reports about the stock. Berenberg Bank upped their price objective on shares of Haleon from GBX 507 to GBX 517 and gave the stock a “buy” rating in a report on Wednesday, November 5th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a GBX 370 target price on shares of Haleon in a report on Friday, October 31st. Jefferies Financial Group restated a “buy” rating and issued a GBX 440 price target on shares of Haleon in a research report on Monday, November 3rd. Finally, The Goldman Sachs Group reiterated a “buy” rating and set a GBX 440 price target on shares of Haleon in a report on Wednesday, September 10th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Haleon currently has an average rating of “Hold” and a consensus price target of GBX 420.40.

Haleon Stock Down 0.6%

Shares of HLN traded down GBX 2.40 during mid-day trading on Wednesday, hitting GBX 372.10. 126,187,203 shares of the company traded hands, compared to its average volume of 24,384,990. Haleon has a 1-year low of GBX 325.10 and a 1-year high of GBX 419.50. The company has a market capitalization of £33.14 billion, a PE ratio of 22.28, a price-to-earnings-growth ratio of 1.49 and a beta of 0.19. The company has a quick ratio of 0.93, a current ratio of 0.84 and a debt-to-equity ratio of 53.36. The business has a 50 day moving average of GBX 349.81 and a 200 day moving average of GBX 367.14.

About Haleon

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other.